Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network.

[1]  Nikki M. Carroll,et al.  Validation of Electronic Data on Chemotherapy and Hormone Therapy Use in HMOs , 2013, Medical care.

[2]  L. Walter,et al.  Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Dhruv B. Sharma,et al.  Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. , 2012, JAMA.

[4]  Roy Pardee,et al.  Validity of Eight Integrated Healthcare Delivery Organizations' Administrative Clinical Data to Capture Breast Cancer Chemotherapy Exposure , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[5]  R. Perez-soler,et al.  Treatment of non-small-cell lung cancer with erlotinib or gefitinib. , 2011, The New England journal of medicine.

[6]  T. Smith,et al.  Using claims‐based measures to predict performance status score in patients with lung cancer , 2011, Cancer.

[7]  E. Li,et al.  Preliminary report: the development of the NCCN Comparative Therapeutic Index™ as a clinical evaluative process for existing data in oncology. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  C. Grady,et al.  How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. , 2009, Journal of the National Cancer Institute.

[9]  M. Stokes,et al.  Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. , 2009, Lung cancer.

[10]  J. Milanowski,et al.  Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[12]  Sarah M. Greene,et al.  Building a virtual cancer research organization. , 2005, Journal of the National Cancer Institute. Monographs.

[13]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Ruth Etzioni,et al.  Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Robert B Wallace,et al.  Population variations in the initial treatment of non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Logistic Regression Using the SAS® System , 2000 .

[17]  M. Weinstein,et al.  Who gets chemotherapy for metastatic lung cancer? , 2000, Chest.

[18]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[19]  B. Burnand,et al.  Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. , 2008, Lung cancer.

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.